A notable example of this category of patients undergoing treatment currently is the one identified with BRCA mutations for breast and ovarian cancer, human epidermal growth factor receptor 2 (HER2), and progesterone receptor (PR) for breast cancer. This evidence concerns the gene ERBB2 and breast cancer.